Clinical Trials Browser

Phase 2 × Interventional × STA 9090 × Clear all

NCT01042379 2026-05-06

I-SPY

Phase 2 Recruiting

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT01560416 2026-03-03

Fulvestrant With or Without Ganetespib in HR+ Breast Cancer

Phase 2 Completed

50 enrolled 14 charts

Breast Neoplasms, Neoplasm Metastasis

NCT03783949 2025-06-11

EUDARIO

Phase 2 Completed

122 enrolled 23 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01167114 2023-11-02

STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancer

Phase 2 Completed

Gastrointestinal

Esophagogastric Cancer

NCT01173523 2019-04-16

Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer

Phase 2 Completed

25 enrolled 8 charts

Recurrence, Small Cell Lung Carcinoma

NCT01200238 2018-10-18

STA-9090(Ganetespib) in Metastatic Ocular Melanoma

Phase 2 Completed

17 enrolled 12 charts

Uveal Melanoma

NCT01270880 2018-09-18

Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

Phase 2 Completed

18 enrolled 8 charts

Prostatic Neoplasms

NCT01551693 2017-04-12

STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma

Phase 2 Terminated

3 enrolled 7 charts

Melanoma, Neoplasm Metastasis

NCT01039519 2016-03-10

A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST)

Phase 2 Completed

27 enrolled 22 charts

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT01111838 2015-11-20

Clinical and Translational Study of STA-9090

Phase 2 Completed

20 enrolled 6 charts

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

NCT01273896 2015-11-20

Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer

Phase 2 Completed

22 enrolled 6 charts

Breast Neoplasms

NCT01677455 2015-11-05

Enchant

Phase 2 Completed

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01368003 2015-09-01

STA-9090 in Castration-Resistant Prostate Cancer With Assessment of Androgen Receptor Pathway Signaling

Phase 2 Withdrawn

Adenocarcinoma of the Prostate

NCT01562015 2015-05-20

CHIARA

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT01031225 2014-09-19

A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01227018 2014-07-23

PhII Study STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas Cancer

Phase 2 Terminated

15 enrolled 9 charts

Gastrointestinal

Pancreatic Neoplasms